Drug Profile
Research programme: diabetes therapy - Crucell
Alternative Names: diabetes therapy research programme - CrucellLatest Information Update: 26 Jan 2005
Price :
$50
*
At a glance
- Originator Crucell; University Medical Center Utrecht
- Class Monoclonal antibodies; Proteins; Vaccines
- Mechanism of Action Islet amyloid polypeptide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 26 Jan 2005 Discontinued - Preclinical for Type-2 diabetes mellitus in Netherlands (unspecified route)
- 21 May 2001 Preclinical development for Type-2 diabetes mellitus in Netherlands (Unknown route)